REPLIGEN CORP (RGEN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RGEN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | President and Chief Executive Officer; Director | 52 | ["Public Company Board/CEO", "Risk Oversight", "Finance & Capital Markets", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Life Sciences Technology & Innovation", "Commercial Sales & Marketing", "Over 30 years of leadership experience across advanced diagnostics, clinical laboratory services and global healthcare technology", "Served as President and CEO and a director of OraSure Technologies, Inc. since 2022", "Senior Vice President, Advanced & General Diagnostics and Clinical Solutions at Quest Diagnostics from 2017 to 2022", "Oversaw value creation across company\u2019s $10 billion clinical portfolio at Quest", "Spent two decades at GE Healthcare with expertise in healthcare, commercial, operational and regulated manufacturing", "Served as President and CEO of four distinct global businesses"] | ["Audit"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| OSUR | President and CEO, OraSure Technologies, Inc.; President and Chief Executive Officer | 52 | ["Extensive leadership experience in the healthcare industry","Proven track record of driving innovation","Scaling complex diagnostic businesses","Delivering strategic growth and transformation across global organizations","Launching and commercializing innovative products and technologies","Integrating acquisitions and building operations excellence","Operational insight for long-term growth strategy and capital allocation"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Member of the Audit Committee. The Board has determined that Ms. Eglinton Manner is independent within the meaning of the Nasdaq Stock Market LLC's director independence standards and the SEC's heightened director independence standards for audit committee members as determined under the Exchange Act.